Outcomes over the first two years of treatment with mepolizumab in severe asthma

This study found that 30% of patients stopped mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab. https://bit.ly/3ChWN63

Detalles Bibliográficos
Autores principales: Elsey, Lynn, Pantin, Thomas, Holmes, Leanne-Jo, Tavernier, Gael, Fowler, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696189/
https://www.ncbi.nlm.nih.gov/pubmed/34711539
http://dx.doi.org/10.1183/13993003.01313-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696189/
https://www.ncbi.nlm.nih.gov/pubmed/34711539
http://dx.doi.org/10.1183/13993003.01313-2021

Ejemplares similares